2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Agitation: new trials by email Literature Review of Agitation trials Research Report on Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) BXCL501, Matching Placebo - Agitation, Dementia | Phase 3 | Terminated | BioXcel Therapeutics Inc | 13 | 2022-12-05 | 2026-10-01 |
| Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia Depakote ER, Seroquel - Agitation, Dementia | Phase 3 | Terminated | Tuscaloosa Research & Education Advancement Corporation | 20 | 2006-05-01 | 2017-04-27 |
Dementia (2) · Psychomotor Agitation (2)
Aberrant Motor Behavior in Dementia (2) · Behavior (2) · Behavioral Symptoms (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Dyskinesias (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurocognitive Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Psychomotor Disorders (2) · Signs and Symptoms (2)
Dexmedetomidine (1) · Quetiapine Fumarate (1) · Valproic Acid (1)
BioXcel Therapeutics Inc (1) · Tuscaloosa Research & Education Advancement Corporation (1)
United States (2)
John L Shuster, MD (1) · Robert Risinger, MD (1)